Scientists discover new epigenetic cause of cblC that shifts rare disease paradigm

Posted: 1 February 2018 | | No comments yet

Researchers in France and Canada have discovered an epigenetic alteration of a vitamin B12 gene – MMACHC – that has significant implications for our understanding of cblC and other rare diseases.


Rare hereditary recessive diseases were thought to be expressed in off-spring only when both parents carry a mutation in the causal gene, but a new study has altered this paradigm. An international research team led by scientists at the University of Lorraine in France along with McGill University and the Research Institute of the McGill University Health Centre (RI-MUHC) in Canada discovered a new cause of a rare condition known as cblC, that they named ‘epi-cblC’.

These cases were reported in Europe and the United States. Patients who have cblC are not able to process vitamin B12 – obtained from animal-based foods and essential for healthy functioning of the human nervous system – which leads to severe health problems.

cblC caused by epimutation

cblC is usually caused by two mutations – one inherited from each parent – in a gene called MMACHC. In some patients, the scientists found this disease actually results from a mutation on a single copy of the gene and the silencing of the second copy by a gene modification referred to as epimutation. This epimutation is produced by a mutation in an adjacent gene. These findings may have an impact on diagnosis, and genetic counselling in families with genetic diseases, as well as in the development of new therapeutic approaches.

Commenting on the effects of the newly discovered gene mutation, Dr. Jean-Louis Guéant, Director of the Inserm unit of Nutrition-Genetics-Environmental Risks at University of Lorraine, said: “We described a distinct and totally new mechanism referred as epi-cblC, whereby an epimutation causes abnormal regulation of the expression of an important vitamin B12 gene. This can result in a serious genetic disease that can cause anaemia, neuro-cognitive impairment, and even early death.”

cblC is the most common of the inborn genetic errors of vitamin B12 metabolism. Based on one newborn patient case, who died from clinical implications of this disease, the scientists from the University of Lorraine identified an epimutation affecting the MMACHC gene that was present in three generations and in the sperm of the fathers of two of the seven patients. The French and Canadian groups subsequently found it in other cases from Europe and North America and discovered that it resulted from the altered reading of the adjacent gene.

“This epimutation observed in patients causes MMACHC to shut down and become inactive. This has the same effect as an actual mutation in the gene itself. This mechanism may be involved in many more diseases,” explains study co-author, Dr. David Rosenblatt, a scientist in the Child Health and Human Development Program at the RI-MUHC and holder of the Dodd Q. Chu and Family Chair in Medical Genetics in the Department of Human Genetics at McGill University.

Cooperative research yields discovery

These results build on a longstanding collaboration between research teams in France and Quebec, along with others in the United States and Switzerland. In previous work, the researchers at the RI-MUHC and McGill discovered that mutations in the MMACHC gene were responsible for the cblC inborn error of vitamin B12 metabolism. Following the study of several hundred patients, there remained a small number in whom only one mutation could be found in MMACHC.

Geneticists and molecular biologists will now need to look for epimutations in patients who have severe forms of rare diseases despite the lack of mutation in one of the two copies of the gene. The mechanism responsible for epimutation involves the two neighbouring genes of MMACHC. Epigenetic mechanisms can also be caused by environmental factors, such as diet, stress, exposure to toxic products, etc., and not merely the chance of genetic mutations.

“We have identified some 40 rare diseases where this mechanism can be produced at the level of similar trios of genes,” says Dr. Guéant, who is also head of the Department of Molecular Medicine and Personalized Therapeutics – National Center of Inborn Errors of Metabolism at the University Regional Hospital of Nancy.

“It points out that the study of patients with rare diseases is essential to the advancement of our knowledge of human biology,” adds Dr. Rosenblatt.